Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie Inc    ABBV

ABBVIE INC (ABBV)

Delayed Quote. Delayed  - 02/24 10:02:11 pm
62.09 USD   +0.24%
02/17 ABBVIE : Announces $5 Billion Increase to Stock Repurchase Program
02/16 ABBVIE : Declares Quarterly Dividend
02/16 UK NATIONAL INS : Abbv)
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/17/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
61.77(c) 61.83(c) 61.36(c) 61.94(c) 62.09(c) Last
8 124 442 8 503 519 6 422 208 8 057 672 6 507 080 Volume
+0.47% +0.10% -0.76% +0.95% +0.24% Change
More quotes
Financials ($)
Sales 2017 27 768 M
EBIT 2017 11 967 M
Net income 2017 7 951 M
Debt 2017 26 577 M
Yield 2017 4,14%
Sales 2018 30 321 M
EBIT 2018 13 760 M
Net income 2018 9 355 M
Debt 2018 22 359 M
Yield 2018 4,56%
P/E ratio 2017 13,09
P/E ratio 2018 11,14
EV / Sales2017 4,52x
EV / Sales2018 4,00x
Capitalization 98 967 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
03/08 | 03:20pmPresentation
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC
02/24 ABBVIE : Declares Quarterly Dividend
02/24 ABBVIE : New Proteomics Study Findings Have Been Reported by Researchers at AbbV..
02/17 ABBVIE : Announces $5 Billion Increase to Stock Repurchase Program
02/16 ABBVIE : Investigators at AbbVie Inc. Describe Findings in Prostate Cancer (Expl..
02/16 ABBVIE : Declares Quarterly Dividend
02/16 ABBVIE : Recent Findings from AbbVie Inc. Provide New Insights into Clinical Tri..
02/16 UK NATIONAL INSTITUTE FOR HEALTH AND : Abbv)
02/16 ABBVIE : NICE does not recommend AbbVie’s leukaemia drug
02/15 ABBVIE : to Present at the Cowen and Company 37th Annual Health Care Conference
02/07DJGilead Posts Profit, Revenue Declines
More news
Sector news : Specialty & Advanced Pharmaceuticals
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE INC 
2015A likely recovery
More Strategies
Latest Tweets
02:37aTies to Gilead, AbbVie and BMS raise questions about hep C drug value studies..
1
02/24Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink
5
02/24Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink  
02/24Ties to Gilead, AbbVie and BMS raise questions about hep C drug value studies.. 
02/24Biotech Forum Daily Digest: Trevena Oversold? Bristol-Myers Squibb On The Blo.. 
More tweets
Qtime:171
News from SeekingAlpha
02/24 BIOTECH FORUM DAILY DIGEST : Trevena Oversold? Bristol-Myers Squibb On The Block..
02/24 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2016 Updat..
02/23 Pitney Bowes, H&R Block, & Mattel Lead 26 'Safe' S&P 500 Dividend Dog Februar..
02/23 Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Updat..
02/23 S&P Aristocrat Dog 'Safe' Yields For February Piloted By AbbVie, Chevron, And..
Advertisement
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,8 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC-1.09%98 967
MERCK KGAA3.88%14 073
KYOWA HAKKO KIRIN CO L..4.14%8 659
JAZZ PHARMACEUTICALS P..24.19%8 152
MALLINCKRODT PLC9.33%5 589
ZHANGZHOU PIENTZEHUANG..4.04%4 173
More Results